Literature DB >> 20409525

Duration of deep vein thrombosis prophylaxis in the surgical patient and its relation to quality issues.

James Muntz1.   

Abstract

BACKGROUND: Venous thromboembolism (VTE) is a major cause of mortality and morbidity in patients after major surgery. The US Acting Surgeon General issued a "call to action" to reduce the number of VTE cases nationwide. DATA SOURCES: PubMed literature searches were performed to identify original studies. RESULTS AND
CONCLUSIONS: Noncompliance with VTE guidelines is common in clinical practice. Thromboprophylaxis is frequently stopped on discharge, not meeting recommendations for standard-duration prophylaxis (7-10 days) because of shorter hospital stays or for extended-duration prophylaxis (10-35 days). Appropriate pharmacologic prophylaxis options for orthopedic surgery patients include the low-molecular-weight heparins (LMWHs), fondaparinux, or warfarin (10-35 days). For patients undergoing abdominal surgery for cancer, the LMWHs are recommended beyond hospitalization (up to 28 days). Performance measures should help establish VTE-prevention policies that close the gap between guideline recommendations and clinical practice in a greater number of hospitals. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20409525     DOI: 10.1016/j.amjsurg.2009.05.045

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  2 in total

1.  Alterations in homeostasis after open surgery. A prospective randomized study.

Authors:  T Dedej; E Lamaj; N Marku; V Ostreni; S Bilali
Journal:  G Chir       Date:  2013 Jul-Aug

2.  Risk of Post-Discharge Venous Thromboembolism and Associated Mortality in General Surgery: A Population-Based Cohort Study Using Linked Hospital and Primary Care Data in England.

Authors:  George Bouras; Elaine Marie Burns; Ann-Marie Howell; Alex Bottle; Thanos Athanasiou; Ara Darzi
Journal:  PLoS One       Date:  2015-12-29       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.